Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 181–190, page 19 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/influence-of-patient-characteristics-on-efficacy-and-safety-of-anti-41352683
Background Lecanemab and donanemab are the first anti-amyloid monoclonal antibodies (mAbs) clinically available as disease-modifying therapies for Alzheimer's disease (AD). However, it remains unclear whether their treatment …
-
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-beta-39432414
According to CDR-SB measurements, lecanemab showed effectiveness in reducing brain amyloid and cognitive decline, with a change from baseline of 1.21. Aducanumab resulted in a decrease of -0.39 (-22%). Bapineuzumab showed no …
-
Clonal expansion of cytotoxic CD8<sup>+</sup> T cells in lecanemab-associated ARIAResearch summary
Research summaries · alzhub.org/study/clonal-expansion-of-cytotoxic-cd8-sup-sup-t-cells-in-lecanemab-0f059906
… anti-amyloid therapies such as lecanemab, yet their underlying biology is poorly defined. To address this, we performed deep multi-omic profiling of peripheral blood mononuclear cells from three Alzheimer’s disease (AD) patients …
-
Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic reviewResearch summary
Research summaries · alzhub.org/study/cost-effectiveness-of-traditional-and-novel-neurotherapeutic-agents-41837605
… galantamine. Aducanumab, lecanemab, and donanemab were not cost-effective in any study. Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, …
-
Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemResearch summary
Research summaries · alzhub.org/study/real-world-characterization-of-amyloid-related-imaging-abnormalities-4202aa20
… of patients receiving lecanemab. Methods In this retrospective cohort study from the Mass General Brigham Alzheimer’s Therapeutic Program, we analyzed data from 468 patients with early Alzheimer’s disease who were at least 90 …
-
Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive ValueResearch summary
Research summaries · alzhub.org/study/adverse-events-as-a-cause-of-unblinding-of-allocated-arms-in-anti-39269842
Anti-amyloid drugs for early Alzheimer's disease, including lecanemab, are associated with adverse events (AEs), such as amyloid-related imaging abnormalities (ARIA)-edema/effusion (E), ARIA-hemorrhage, and infusion-related …
-
Research summaries · alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-anti-amyloid-therapies-912127c4
… about 12.6%/17.3% of lecanemab patients and 24%/31% of donanemab patients; most cases are mild or symptom-free and caught on routine MRI, but in roughly 1-2% of cases ARIA has caused permanent disability or death. People with two …
-
Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's DiseaseResearch summary
Research summaries · alzhub.org/study/use-of-model-based-meta-analysis-to-inform-the-design-of-early-40344388
… data on aducanumab, lecanemab, and donanemab. A non-linear mixed effect model with shared model parameters described the dose response data from aducanumab, lecanemab, and donanemab studies after adjusting for different potency …
-
A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's DiseaseResearch summary
Research summaries · alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-40621323
… inclusion criteria. Lecanemab reduced amyloid burden with 81% of patients achieving amyloid-negative PET scans (Clarity AD trial) and showed a 27% reduction in cognitive decline on the ADCOMS scale. While statistically …
-
Research summaries · alzhub.org/study/comparative-efficacy-and-safety-of-monoclonal-antibodies-for-38429615
… ADAS-Cog, and PET-SUVr) and lecanemab (statistically improved ADCS-ADL). Background Recent clinical trials of anti-Aβ monoclonal antibodies (mAbs) in the treatment of early Alzheimer's disease (AD) have produced encouraging …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.